These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7277199)

  • 1. Nonlinear first-pass metabolism of propranolol in the rat.
    Suzuki T; Ohkuma T; Isozaki S
    J Pharmacobiodyn; 1981 Feb; 4(2):131-41. PubMed ID: 7277199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the route of administration on the mean hepatic extraction ratio of propranolol in the rat.
    Suzuki T; Isozaki S; Ohkuma T; Rikihisa T
    J Pharmacobiodyn; 1980 Nov; 3(11):603-11. PubMed ID: 7241334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent presystemic elimination of propranolol due to hepatic first-pass metabolism in rats.
    Iwamoto K; Watanabe J
    J Pharm Pharmacol; 1985 Nov; 37(11):826-8. PubMed ID: 2867168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation.
    Ghabrial H; Nand R; Stead CK; Smallwood RA; Morgan DJ
    J Pharm Sci; 1994 Jul; 83(7):931-6. PubMed ID: 7965671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.
    Letendre L; Scott M; Dobson G; Hidalgo I; Aungst B
    Pharm Res; 2004 Aug; 21(8):1457-62. PubMed ID: 15359582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythrocytes as barriers for drug elimination in the isolated rat liver. II. Propranolol.
    Lee HJ; Chiou WL
    Pharm Res; 1989 Oct; 6(10):840-3. PubMed ID: 2608625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of route of administration and blood flow on hepatic drug elimination.
    Shand DG; Kornhauser DM; Wilkinson GR
    J Pharmacol Exp Ther; 1975 Dec; 195(3):424-32. PubMed ID: 1195129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood.
    Terao N; Shen DD
    J Pharmacol Exp Ther; 1985 May; 233(2):277-84. PubMed ID: 3999018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
    Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG
    J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The increased intestinal absorption rate is responsible for the reduced hepatic first-pass extraction of propranolol in rats with cisplatin-induced renal dysfunction.
    Okabe H; Mizukami A; Taguchi M; Aiba T; Yasuhara M; Hashimoto Y
    J Pharm Pharmacol; 2003 Apr; 55(4):479-86. PubMed ID: 12803769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
    Kim SH; Lee MG
    Life Sci; 2002 Feb; 70(11):1299-315. PubMed ID: 11883708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.
    Yang SH; Lee MG
    Biopharm Drug Dispos; 2008 Oct; 29(7):414-26. PubMed ID: 18697186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent. II. Influence of the route of administration on bioavailability in dogs.
    Yoshimura M; Kojima J; Ito T; Fujii M; Suzuki J
    J Pharmacobiodyn; 1985 Jul; 8(7):503-12. PubMed ID: 4067813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent pharmacokinetics of a new reversible proton pump inhibitor, DBM-819, after intravenous and oral administration to rats: hepatic first-pass effect.
    Kim EJ; Kim SO; Lee DH; Lim H; Lee MG
    Biopharm Drug Dispos; 2001 Apr; 22(3):119-28. PubMed ID: 11745914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of propranolol on hepatic haemodynamics in the cirrhotic and non-cirrhotic rat.
    Jenkins SA; Baxter JN; Johnson JN; Devitt P; Shields R
    Br J Surg; 1985 May; 72(5):354-8. PubMed ID: 3995241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic and intestinal first-pass effects of oltipraz in rats.
    Bae SK; Kim JW; Kim YH; Kim YG; Kim SG; Lee MG
    Biopharm Drug Dispos; 2005 May; 26(4):129-34. PubMed ID: 15744718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic and intestinal first-pass effects of a new hepatoprotective agent, YH439, in rats.
    Kim J; Han KS; Lee JW; Lee MG
    Res Commun Mol Pathol Pharmacol; 1998 Nov; 102(2):125-36. PubMed ID: 10100504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A computer simulation of the food effect: transient changes in hepatic blood flow and Michaelis-Menten parameters as mediators of hepatic first pass metabolism and bioavailability of propranolol.
    Semple HA; Tam YK; Coutts RT
    Biopharm Drug Dispos; 1990; 11(1):61-76. PubMed ID: 2322637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of chlorpromazine, metyrapone, imipramine and SKF 525-A on the hepatic first pass elimination of propranolol in the pithed rat.
    Barber HE; Kitteringham NR; Petrie JC
    Br J Pharmacol; 1982 Dec; 77(4):667-77. PubMed ID: 7150874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.